Affiliation:
1. Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, School of Pharmacy, Zunyi Medical University, Guizhou 563009, China
2. China–Japan Friendship Hospital, Beijing 100029, China
3. Community Health Service Center of Chaoyangmen, Dongcheng, Beijing 100036, China
4. Hefei Qixing Pharmaceutical Medicine and Technology Co., Ltd.; Hefei 230032, China
Abstract
Background:
Vitexin is the main bioactive compound of hawthorn (Crataegus pinnatifida),
a famous traditional Chinese medicine, and vitexin for injection is currently in phase I clinical
trial in China.
Objective:
This investigation systematically evaluated the metabolism and toxicokinetics of vitexin
in rats and dogs.
Methods:
Rats and beagle dogs were administrated different doses of vitexin, and then the plasma
concentration, tissue distribution, excretion, metabolism, pharmacokinetics and plasma protein
binding were investigated.
Results :
The elimination half-life (t1/2) values in rats after a single intravenous dose of 3, 15 and 75
mg/kg were estimated as 43.53±10.82, 22.86±4.23, and 21.17±8.64 min, and the values of the area
under the plasma concentration-time curve (AUC0→∞) were 329.34±144.07, 974.79±177.27, and
5251.49±786.98 mg•min/L, respectively. The plasma protein binding rate in rats was determined
as about 65% by equilibrium dialysis after 72 hr. After 24 hr of intravenous administration,
16.30%, 3.47% and 9.72% of the given dose were excreted in urine, feces and bile, respectively.
The metabolites of the vitexin were hydrolyzed via deglycosylation. The pharmacokinetics of dogs
after intravenous administration revealed t1/2, AUC0-∞ and mean residence time (MRT0-∞) values of
20.43±6.37 min, 227.96±26.68 mg•min/L and 17.12±4.33 min, respectively. The no-observed-adverse-
effect level (NOAEL) was 50 mg/kg body weight/day. There was no significant accumulation
effect at 8 or 20 mg/kg/day in dogs over 92 days of repeated administration. For the 50 mg/kg/-
day dose group, the exposure (AUC, Cmax) decreased significantly with prolonged administration.
This trend suggests that repeated administration accelerates vitexin metabolism.
Conclusion:
The absorption of vitexin following routine oral administration was very low. To improve
the bioavailability of vitexin, the development of an injectable formulation would be a suitable
alternative choice.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Molecular Medicine,Biochemistry,Biophysics
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献